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Introduction
In postmenopausal women with early breast cancer, the 
third-generation aromatase inhibitors (AIs; anastrozole, 
exemestane, and letrozole) have been proven to be of 
value in multiple large well-conducted clinical trials as 
initial adjuvant endocrine therapy, after several years of 
tamoxifen, and as extended adjuvant endocrine therapy 
after about 5 years of tamoxifen [1-8]. A recent American 
Society of Clinical Oncology clinical practice guideline 
stated that an AI should be used in the adjuvant setting 
either initially or after some period of tamoxifen therapy [9].
Despite the proven value of the AIs, many women are 
not adherent [10]. About one-half of women treated with 
an AI have new or worsening joint complaints [11]. Th  e 
importance of musculoskeletal complaints was identiﬁ  ed 
in reviewing the experience with MA.27, a large phase III 
trial comparing the non-steroidal AI anastrozole with the 
steroidal AI exemestane as adjuvant therapy for early 
breast cancer. Th  ese musculoskeletal adverse events 
(MS-AEs) were the most common reason why patients 
discontinued AI therapy. We had previously demon-
strated marked variability in metabolism and pharmaco-
dynamics of one of the AIs, anastrozole [12]. We hypo-
the  sized that the variability seen with respect to MS-AEs 
in women treated with anastrozole or exemestane on 
MA.27 could be related to genetic variability of the 
patients. We proceeded to perform a genome-wide 
association study (GWAS) aimed at identifying SNPs 
associated with MS-AEs. Th   e results of this GWAS and 
the functional genomic laboratory studies performed 
have recently been published [13]. Th   is short communi-
cation summarizes the highlights of this work plus a 
commentary on future pharmacogenomic studies of anti-
cancer agents.
Methods
MA.27 is a randomized clinical trial conducted by the 
Breast Cancer Intergroup of North America that was 
coordinated by the NCIC Clinical Trials Group [13]. Eligible 
patients were those with a postmenopausal status and 
resected American Joint Committee on Cancer (version 6) 
stage I to III breast cancer that was hormone receptor 
positive. Patients were randomized to anastro  zole or 
exemestane for a period of 5 years. A total of 6,827 women 
in North America were randomized and the majority 
provided DNA and consent for its use in genetic studies.
Cases were deﬁ  ned as those patients who developed a 
MS-AE, as previously deﬁ   ned [13], and each case was 
matched to two controls. Th   e design utilized was a nested 
matched cas    e-control study and the primary analyses were 
based on conditional logistic regression. Th  e RIKEN 
Center for Genomic Medicine performed genotyping with 
the Illumina Human610-Quad platform. Imputation and 
ﬁ  ne mapping were performed in the region of interest on 
chromosome 14 containing the SNPs with the smallest P-
values. Functional genomic studies, relating to the SNPs 
on chromosome 14, were performed using electrophoretic 
motility shift (EMS) assays, chromatin immuno  preci  pi-
tation (ChIP) assays, and transfection studies.
Results
We studied 293 cases and 585 controls, and cases and 
controls were well balanced for all factors except prior 
hormone replacement therapy, which was signiﬁ  cantly 
higher in cases than controls (66% versus 44%), and 
fractures within the past 10 years, which were slightly 
higher in cases than controls (13% versus 9%). A total of 
551,395 SNPs were used in the association analyses after 
exclusion of genotype failures (n = 11,281), SNPs with a 
minor allele frequency <0.01 (n = 29,478), and SNPs with a 
departure (P < 1E-06) from Hardy-Weinberg equili brium 
(n = 82). Th   e conditional logistic regression analy  ses were 
adjusted for population stratiﬁ  cation and revealed three 
SNPs (rs7158782, rs7159713, rs2369049) on chromosome  © 2010 BioMed Central Ltd
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values (7.74E-07 to 2.23E-06), which approach the 
Bonferroni threshold of 1E-07. Subse  quently, imputation 
and ﬁ  ne mapping revealed an additional SNP (rs11849538), 
also on chromosome 14 and in high linkage disequilibrium 
with the three geno  typed SNPS, with the smallest P-value 
(6.67E-07). Th  ese four SNPs were all found to be close 
(that is, within 7,109 bp) of the 3’ end of the T-cell 
leukemia 1A (TCL1A) gene with the closest SNP 
(rs11849538) being only 926 bp away.
Initially, we determined that TCL1A is variably 
expressed in 288 lymphoblastoid cell lines from three 
diﬀ   erent ethnic groups for which we have expression 
array and genome-wide SNP data. Functional genomic 
studies were performed with the three genotyped SNPs 
and the one imputed/ﬁ  ne mapped SNP to examine for 
any functional signiﬁ  cance. Lymphoblastoid cell nuclear 
extract used in EMS assays showed a ‘shift’, that is, 
protein binding, for three of the SNPs (rs11849538, 
rs7158782, rs7159713) with less binding by the variant 
than wild-type sequences. Of particular interest as it 
relates to a drug that lowers estrogen levels, a TRANSFAC 
database search predicted that the SNP (rs11849538) 
with the smallest P-value would create an estrogen 
response element and this was conﬁ  rmed with a ChIP 
assay utilizing lymphoblastoid cells with known genotype 
for this SNP that had been transfected with estrogen 
receptor (ER)α. TCL1A expression was linked to estrogen 
by exposing U20S cells that had been stably transfected 
with ERα or ERβ to 0.1 nM E2, and demon  strating eight- 
and six-fold increases in TCL1A mRNA expression after 
18 hours and 1 hour, respectively. To determine the eﬀ  ect 
of these four SNPs on estrogen-dependent TCL1A 
expres  sion, lymphoblastoid cell lines with genotypes 
known for the four SNPs were transiently transfected with 
ERα and exposed to various concen  trations of estradiol. 
All three ethnic groups showed greater TCL1A expression 
with the variant than the wild-type sequence. Because the 
clinical picture of the MS-AEs is reminiscent of a chronic 
inﬂ   ammatory state, we utilized the same 288 lympho-
blastoid cell lines noted above and determined the 
correlation between TCL1A expression and expres  sion of 
IL17 and the IL17 receptor A (IL17RA). Remark  ably, 
TCL1A and IL7RA expression were highly correlated 
(P < 1.9E-10). In studies using U20S cells transfected with 
either ERα or ERβ, small interfering RNA (siRNA) 
knockdown of TCL1A resulted in decreased expression of 
IL17RA but increased expression of IL17, whereas TCL1A 
overexpression resulted in increased IL17RA expression 
and decreased expression of IL17.
Discussion
We identiﬁ  ed four SNPs on chromosome 14 that were 
associated with MS-AEs in women receiving AIs as 
adjuvant therapy for early-stage breast cancer. Given that 
AIs perturb estrogen levels in these women, we examined 
the relationship between the SNPs and estrogen action. 
Of particular note is that the SNP with the smallest P-
value (rs11849538) created an estrogen response element 
that was shown by ChIP assay to be functional. Estrogens 
induced TCL1A expression that was signiﬁ  cantly higher 
in cells with the variant SNPs than those with the wild-
type sequence. Expression of TCL1A was directly asso-
ciated with IL17RA expression in that siRNA knockdown 
of  TCL1A resulted in decreased expression of IL17RA 
and increased expression of IL17 whereas overexpression 
of TCL1A resulted in increased expression of IL17RA 
and decreased expression of IL17.
Th  e identiﬁ   cation of a relationship between TCL1A 
expression and the inﬂ   ammatory cytokine IL17 is 
particu  larly noteworthy given the recent identiﬁ  cation of 
a third lineage of T-helper cells (in addition to Th  1  and 
Th  2), that is, Th  17, that is associated with chronic 
inﬂ  ammation [14], and in which IL17 plays a central role. 
IL17 and IL17RA represent potential targets and eﬀ  orts 
to target these factors in a variety of inﬂ  ammatory 
diseases are in progress (reviewed in [14]).
Th  e study reported here demonstrates the value of 
GWASs. A GWAS is, by deﬁ  nition, a ‘hypothesis-free’ 
interrogation of the entire genome and, in our study, 
identiﬁ  ed a gene, TCL1A, which was totally unexpected. 
However, it was clearly necessary to perform the func-
tional genomic studies to begin to understand the 
potential biologic implications of these ﬁ  ndings. Clearly, 
replication is an important consideration in the perfor-
mance of a GWAS because of the problem of false 
positive associations [15]. Th  e replication of genome-
wide pharmacogenomic studies of anti-cancer agents will 
likely be found to be substantially more problematic than 
genome-wide studies examining risk of developing a 
cancer. For example, in a recent study to identify breast 
cancer susceptibility alleles, a GWAS was performed in 
3,659 cases and 4,897 controls, and then promising asso-
ciations were then studied in 12,576 cases and 12,223 
controls [16]. In the case of pharmacogenomic studies of 
anti-cancer agents, a GWAS will likely be best conducted 
utilizing patients entered into a prospectively conducted 
clinical trial. MA.27, the study from which the patients in 
our GWAS were obtained, is such a trial but is the largest 
study conducted of AIs alone, taking 8 years to complete 
at a cost of tens of millions of dollars. Replication will not 
be possible utilizing a larger cohort of patients as it 
simply does not exist. Although the conduct of rigorous 
and insightful functional genomic studies can be viewed 
as important in pursuing leads from any GWAS, such 
studies may have greater importance in the case of anti-
cancer agents because of limitations imposed by a relative 
paucity of patient cohorts, at least compared to studies 
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developing cancer.
In conclusion, our GWAS identiﬁ  ed four SNPs related 
to MS-AEs in women receiving AIs as adjuvant therapy 
for their early breast cancer. Th   ese SNPs were related to 
TCL1A, which in turn was related to the inﬂ  ammatory 
cytokine IL17. Further work is ongoing in our laboratory 
to expand our understanding of the mechanisms involved 
in the TCL1A-IL17 relationship. Ultimately, this new 
know  ledge should help identify means to ameliorate the 
AI-related MS-AEs in order to allow more women with 
early breast cancer to take these potentially life-saving 
drugs.
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